Overview of the effects and side effects of pemetinib in the treatment of cholangiocarcinoma

Pemetinib, a new targeted drug developed byIncyte Biopharmaceutical Company, brings new treatment options to patients with locally advanced or metastatic cholangiocarcinoma with FGFR2 gene fusion or rearrangement. Cholangiocarcinoma, a rare malignant tumor that forms in the bile ducts, has long been difficult to treat. The emergence of pemetinib has brought new treatment hope to these patients.

Based on the clinical data ofFIGHT-202 study, the US FDA has officially approved pemetinib for the treatment of patients with related cholangiocarcinoma. This study is a multicenter, open-label, single-arm clinical trial designed to evaluate the therapeutic effect of pemetinib in adult patients with cholangiocarcinoma. The study results showed that for patients carrying FGFR2 fusions or rearrangements, pemetinib monotherapy achieved an overall response rate of 36%, and the median duration of response reached 9.1 months. This data fully demonstrates its significant therapeutic effect.

However, as with all medications, the use of pemetinib may be associated with a range of potential side effects. Based on observations from clinical trials, patients taking pemetinib may experience common side effects such as hair loss, diarrhea, nail abnormalities (including nails that separate from the bed or are poorly formed), fatigue, taste changes, nausea, constipation, mouth ulcers, dry eyes, dry mouth, decreased appetite, vomiting, joint pain, stomach pain, and reduced phosphate levels in the blood. In addition, there are some relatively serious side effects that require special attention, such as vision problems (blurred vision, flashes of light or black spots), hyperphosphatemia (which may cause muscle spasms, numbness or tingling around the mouth), etc.

Therefore, patients should always pay attention to their physical condition while receiving pemetinib treatment, and report any discomfort or abnormal reaction to their doctor immediately if they notice any discomfort or abnormal reaction. The doctor will adjust the drug dosage or take other necessary measures to reduce the impact of side effects in a timely manner based on the patient's specific condition. At the same time, regular blood tests and eye exams are essential to monitor the potential effects of medications on the body.

Overall, pemetinib provides a new treatment option for patients with cholangiocarcinoma, and its therapeutic effect is remarkable. However, patients need to be alert to possible side effects during use and conduct treatment under the guidance of a doctor to ensure the safety and effectiveness of the treatment. As for the price of the drug, the price of the original drug of pemetinib in the current market is relatively high, with a box selling for about tens of thousands of yuan, while the generic drug is relatively cheaper, and patients can make a choice based on their own circumstances.